Oxidative phenol cross-linking reactions play a key role in the biosynthesis of glycopeptide antibiotics such as vancomycin. The vancomycin aglycone contains three cross-links between aromatic amino acid side-chains, which stabilize the folded backbone conformation required for binding to the target D-Ala-D-Ala dipeptide. At least the first cross-link is introduced into a peptide precursor whilst it is still bound as a thioester to a peptide carrier protein (PCP) domain (also called a thiolation domain) within the nonribosomal peptide synthetase. We described here methods for the solid-phase synthesis of peptides and their coupling to PCP domains, which may be useful for in vitro studies of cross-linking and related tailoring reactions during nonribosomal glycopeptide antibiotic biosynthesis. 
Introduction
One of the strategies used in Nature to create conformationally constrained peptides involves oxidative cross-linking of aromatic amino acid side chains. Examples are found in the glycopeptide antibiotics, such as vancomycin and teicoplanin ( Figure-1) , which contain biaryl ether (C-O-C) as well as direct biaryl (C-C) cross-links (Hubbard and Walsh, 2003) .
These are essential for the creation within the glycopeptide scaffold of a binding site for the dipeptide D-Ala-D-Ala found in intermediates of bacterial peptidoglycan biosynthesis. Such aromatic C-O-C and C-C cross-links, however, occur more widely in Nature, for example, in the closely related bacterial metabolites complestatin (Seto et al., 1989) , kistamicin (Naruse et al., 1993) and chloropeptin (Matsuzaki et al., 1994) , as well as in peptidic natural products such K-13 (Yasuzawa et al., 1987) , bouvardin (Jolad et al., 1977) and the related plant metabolites RA-I-XVI (Hitotsuyanagi et al., 2004) , OF4949 (Sano et al., 1986) , the arylomycins (Holtzel et al., 2002) , the biphenomycins (Uchida et al., 1985) , the TMC-95 family (Kohno et al., 2000) , and RP-664536 (Helynck et al., 1998) .
Figure-1.
Oxidative phenol coupling reactions also play a key role in plant alkaloid biosynthesis, especially benzylisoquinoline alkaloids such as morphine (Ziegler and Facchini, 2008) . The first report of the purification and cloning of a cytochrome P450 enzyme catalyzing a regio and stereospecific oxidative C-O-C phenol coupling was of berbamunine synthase from Berberis stolonifera (Kraus and Kutchan, 1995) . A related P450 catalyzing a C-C coupling was cloned recently from Coptis japonica, which converts (S)-reticuline into (S)-corytuberine (Ikezawa et al., 2008) . These plant enzymes, however, appear to be membrane bound proteins. In contrast, several soluble microbial P450 enzymes have also been cloned and studied recently that catalyze phenol (and related) coupling reactions. These include a flaviolin oxidase (Zhao et al., 2005) , a tetrahydroxynaphthalene oxidase (Funa et al., 2005) , an indole-indole coupling enzyme (StaP) involved in staurosporine biosynthesis (Howard-Jones and Walsh, 2007; Makino et al., 2007) , and last but not least, the enzyme OxyB, which catalyzes the first cross-linking step in the biosynthesis of vancomycin and related glycopeptides (Woithe et al., 2007; Zerbe et al., 2004) .
The three oxidative cross-linking reactions during vancomycin biosynthesis are catalyzed in a defined order by three closely related cytochrome P450s, called OxyA, OxyB and OxyC (following the order of their genes in the bacterial chromosome). The first coupling reaction occurs between the phenol rings in residues-4 and -6 (the C-O-D ring), catalyzed by OxyB, the second aryl-ether bridge is formed between side chains of residues-2 and -4 (D-O-E ring) by OxyA, and the last biaryl coupling between the aromatic side chains of residues-5 and -7 is carried out by OxyC (AB ring, Figure-1 ) (Bischoff et al., 2001a; Bischoff et al., 2001b; Sussmuth et al., 1999) . The crystal structures of OxyB (CYP165B1) and OxyC (CYP165C1) from the vancomycin producer A. orientalis have been reported in substrate free forms (Pylypenko et al., 2003; Zerbe et al., 2002) , confirming that these proteins indeed contain a fold and heme environment typical of P450 enzymes.
Figure-2.
The heptapeptide backbones of glycopeptides are constructed by the actions of large non-ribosomal peptide synthetase (NRPS) multidomain proteins (NRPS-1, -2 and -3, Figure- 2). According to the so-called thiotemplate mechanism of assembly, peptidic intermediates remain bound as C-terminal thioesters to pantetheinyl groups attached to peptide carrier protein (PCP) domains (also called thiolation, or T domains) within the NRPS assembly line (Grünewald and Marahiel, 2006) . Each module in the NRPS is responsible for the incorporation of one amino acid, and contains at least a PCP domain and an amino acid activating (A) domain, usually also a condensation (C) domain, and sometimes also an epimerization (E) domain amongst others. Seven modules are required to assemble glycopeptide heptapeptide backbones, which according to bioinformatic analyses are distributed between three (in a 3:3:1 distribution) or four (in a 2:1:3:1 distribution) NRPS subunits for the vancomycin-like and teicoplanin/complestatin-type glycopeptides, respectively (Donadio et al., 2005) . Fused to module 7 is a domain (X) of unknown function and a thioesterase (TE) domain. Only recently has it become clear that whilst being shuffled along and remaining covalently anchored to the NRPS assembly line, the peptide intermediates may also be transformed by other enzymes acting in trans. This has been demonstrated in vitro for OxyB in vancomycin-like glycopeptides (Woithe et al., 2007; Zerbe et al., 2004) , and may well also be true for the other cross-linking enzymes, and the halogenases which introduce Cl atoms into aromatic residues during glycopeptide biosynthesis.
For in vitro studies of glycopeptide cross-linking and halogenase enzymes access is required to suitable substrates, namely, peptides linked as thioesters to fragments of the NRPS, in particular, isolated recombinant PCP domains (Figure-2 ). The production of such peptide-PCP conjugates is often not straightforward, due to the stereochemical and chemical lability of these molecules. The approach described here involves first the solid-phase synthesis of a suitable peptide (Figure-3 ).
Figure-3.
The required synthetic peptides typically contain hydroxyphenylglycine (Hpg) and ß-hydroxytyrosine (Bht) derivatives, which are often rapidly epimerized and/or degraded upon treatment with acids and bases. Thus, the peptides cannot be synthesized efficiently using standard Fmoc-and Boc-methods of solid-phase peptide synthesis. Next, the peptide should be activated at the C-terminus, first as an S-phenyl and then an S-CoA thioester. With the peptide-SCoA thioester, the broad specificity pantetheinyl transferase Sfp from B. subtilis (Quadri et al., 1998) can be used to transfer the entire peptide-pantetheinyl portion to the active site Ser residue of a recombinant apo-PCP domain. Finally, a suitable fragment of the NRPS comprising an intact PCP domain must be produced in the apo-form. Although powerful general methods exist for producing large amounts of protein in the cytoplasm of E. coli, the expression protocol used and the choice of N-and C-termini for the PCP domain can have a major influence on its folding and solubility in aqueous buffers. Below, we expand on one approach for synthesizing such molecules, which has been validated recently in the production of a variety of peptide-PCP conjugates for in vitro studies of glycopeptide antibiotic cross-linking enzymes Woithe et al., 2008; Woithe et al., 2007 ).
Peptide Synthesis
As a typical example, we focus here on the model hexapeptide 1 (Figure-4 ) and its use for in vitro assays with OxyB. The methods described here for the production of 1 and its PCPbound form (1-S-PCP) can, however, be readily adapted for the production of a variety of other related peptide-PCP conjugates. In the interests of ease of synthesis, ß-hydroxytyrosine is incorporated only at position-6 of this hexapeptide, although the biosynthetic logic ( Figure- 2) dictates that ß-hydroxytyrosine, or perhaps m-chloro-ß-hydroxytyrosine, should be present at both positions-2 and -6. In earlier studies, model substrates containing tyrosine at both positions-2 and -6 were produced and used for in vitro studies of OxyB Woithe et al., 2008; Woithe et al., 2007; Zerbe et al., 2004) . Also for synthetic convenience, the peptide 1 has an N-methylated D-Leu at the N-terminus. Experience has shown that an unprotected N-terminal N-methylamino group is compatible with thioester formation at the C-terminus, under the conditions used. Note, however, that N-methylation occurs late in the vancomycin biosynthetic pathway, after aglycone formation is complete (O'Brien et al., 2000) , and that the N-methyl group does not influence to any significant extent the crosslinking reaction catalyzed by OxyB Woithe et al., 2007) .
Figure-4.
If peptides are required with an unmethylated N-terminus, then the N-terminal primary amino group should be protected such as with a t-butoxycarbonyl (Boc) group during thioester formation at the C-terminus (Figure-3) . The Boc group can be removed from the peptide after formation of an S-phenyl thioester by brief treatment with TFA (Woithe et al., 2007) .
The free linear peptide 1-OH is first prepared by solid-phase peptide synthesis. The assembly of 1-OH can be achieved efficiently using N-allyloxycarbonyl (Alloc) protected amino acids by solid-phase synthesis on chlorotrityl chloride (CT) resin (Freund and Robinson, 1999; Li and Robinson, 2005) . Where necessary, N-Alloc and side chain O-allyl protecting groups can be removed using Pd-catalysis under neutral conditions. Here, an effort has been made to avoid as far as possible side chain protecting groups, since some (e.g. benzyl groups) can be very difficult to remove cleanly from such labile peptides. The side chain protection of Asn is also avoided, but then exposure to the normal activating reagents (e.g. HBTU/HOBt) can lead to side reactions in the Asn side chain amide, so this and the amino acids subsequently added to the peptide on the resin are coupled as pentafluorophenyl (Pfp) esters. When assembly is complete, only minimal exposure of the resin to acid is needed (0.6% TFA in CH 2 Cl 2 ) to release the fully assembled peptide (1-OH) into solution, which can be purified and used for further studies. Hence, the protected amino acids required for the synthesis of 1-OH are those shown in Figure-4 . Below the synthesis of peptide 1-OH is described in detail.
All synthetic transformations must be performed in a well-ventilated fume hood designed for organic synthesis use, and carried out only by suitably trained personnel.
Avoid direct contact with all chemicals used.
Step-1. Synthesis of amino acid 2. The protected amino acid (Bht) 2 can be prepared using Evans aldol chemistry, as shown in Figure-5 (Evans and Weber, 1986; Evans and Weber, 1987) . The allyl group was chosen for protection of the phenol, since it can be removed under neutral conditions with Pd-catalysis during cleavage of the N-Alloc group.
Figure-5.
Compound 9 was prepared as follows. Stannous triflate (5.0 g, 12 mmol) and dry THF (70 ml) were cooled to -78 o C under Ar. N-Ethylpiperidine (2.5 ml, 18 mmol) was added slowly, and stirred for 5 min. The oxazolidinone 7 (2.76 g, 10 mmol) was added in dry THF at -78 o C, and the mixture was stirred for 1.5 h. The aldehyde 8 was then added, and the mixture was stirred at -78 o C for 2 h. The reaction was quenched by addition of sodium phosphate buffer pH 7, filtered through celite, and the aqueous phase extracted with CH 2 Cl 2 .
The organic extract was washed with 1N aqueous sodium bisulphate, dried over anhydrous sodium sulfate, and concentrated in vacuo. The product was purified by flash chromatography on silica gel (n-hexane:EtOAc, 2:1, R f 0.3) to give 9 as a white foam (3.39 g, 77% To the aldol adduct 9 (3.39 g, 7.74 mmol) in anhydrous MeOH (20 ml) and CH 2 Cl 2 (20 ml) at 0 o C was added a suspension formed by the addition of MeMgBr (2.66 ml, 8.51 mmol) in dry diethylether (3.2 M) to anhydrous MeOH (10 ml) (Evans and Weber, 1987) .
After stirring for 10 min, the reaction was quenched by addition of 1N aqueous sodium bisulfate. The volatile solvent was removed in vacuo, and the aqueous phase was extracted three times with CH 2 Cl 2 . The combined organic phase was then dried over anhydrous sodium sulfate and evaporated in vacuo. The product was purified by flash chromatography on silica gel (n-hexane:EtOAc, 2:1, R f 0.3) to give 10 as a light yellow oil (1.72 g, 76%). To the methyl ester 10 (1.72 g, 5.87 mmol) in dry CH 2 Cl 2 (20 ml) was added Boc 2 O (1.41 g, 6.45 mmol) and 4-(dimethylamino)-pyridine (36 mg, 0.29 mmol). The mixture was stirred at room temperature for 1 h. After cooling to 0 o C, a 30% solution of H 2 O 2 (5 ml) and formic acid (5 ml) were added and the mixture was stirred vigorously for 30 min. Then 1N aqueous sodium bisulphate was added, the organic layer was separated, and the aqueous phase was extracted 3 times with CH 2 Cl 2 . The organic phases were combined, dried over anhydrous sodium sulfate and concentrated in vacuo. The product was purified by flash chromatography on silica gel (n-hexane:EtOAc, 2:1, R f 0.5) to give 11 as a colorless oil (1.12 g, 51%). To compound 11 (1.12g, 2.98 mmol) dissolved in dioxane (20 ml) at room temperature was added a 2N aqueous LiOH solution (7.45 ml, 14.9 mmol) and the resulting mixture was stirred overnight. dissolved in 4N HCl in dry dioxane (5 ml). After stirring for 1h at room temperature, the solution was evaporated to dryness in vacuo to afford the amino acid hydrochloride salt.
In preparation for the formation of 2, allyloxycarbonyl-N-hydroxysuccinimide ester (Alloc-OSu) was prepared (Hayakawa et al., 1986) . Thus, to allyloxycarbonyl chloride (170 µl, 1.6 mmol) and N-hydroxysuccinimide (184 mg, 1.6 mmol) in dry THF (2 ml) was added dropwise over 5 min triethylamine (223 µl, 1.6 mmol). After stirring for 30 min at room temperature, the solution was filtered, and the clear filtrate was evaporated to dryness in vacuo to afford Alloc-OSu, which was used immediatley without further purification.
The amino acid-HCl salt from above (1.67 mmol) and sodium bicarbonate (335 mg, 4.1 mmol) in a mixture of water (5 ml) and acetone (5 ml) was added to the freshly prepared Alloc-OSu, and the mixture was stirred at room temperature overnight. The volatiles were removed in vacuo, then the pH was adjusted to 2 with dil. HCl and the remaining aqueous solution was extracted with EtOAc. The organic extracts were dried over anhydrous sodium sulfate and evaporated to dryness in vacuo to afford 2 (320 mg, 60%) as a white solid. Step-2. Synthesis of amino acid 3. To a stirred solution of D-4-hydroxyphenylglycine (3.34 g, 20 mmol) and sodium bicarbonate (2.4 g, 14 mmol) in water/acetone (1:1, 80 ml) was added freshly prepared Alloc-OSu (3.98 g, 20 mmol) (see above) (Paquet, 1982) . The mixture was stirred for 5 h. The pH was then adjusted to 2 with dil. HCl, and after removal of acetone in vacuo, the aqueous layer was extracted with EtOAc. The extracts were dried over anhydrous sodium sulfate, and evaporated to afford an oil, which was crystallized from ether/hexane to give a white solid (3.88 g, 77% Step-3. Synthesis of amino acid 4. Alloc-Asn-OH was first prepared from Asn using the procedure described in step-2. The pentafluorophenyl (-OPfp) ester was then prepared as follows. To a stirred solution of Alloc-Asn-OH (1.3 g, 6 mmol) and pentafluorophenol (3.68 g, 20 mmol) in dry dioxane (20 ml) at 0 o C was added dicyclohexylcarbodiimide (1.51 g, 7.2 mmol). The mixture was stirred at 0 o C for 2 h and at room temperature for 3 h. The urea was then filtered off, solvent was removed in vacuo, the residue was triturated with n-hexane, and the resulting solid was recrystallized from n-hexane/EtOAc to give the product as a white solid (1.41 g, 61%), which is used directly without purification. Step-4. Synthesis of amino acid 5. The amino acid 5 is prepared in five steps from D-tyrosine.
First, acetyl chloride (5.6 ml, 72 mmol) was added dropwise to methanol (30 ml) and stirred Second, the D-Tyr-OMe.HCl salt prepared as above (4.47 g, 19 mmol) was dissolved in acetone/water (1:1, 40 ml) and sodium bicarbonate (4.0 g, 48 mmol) was added, followed by freshly prepared Alloc-OSu (3.98 g, 20 mmol, prepared as above). The mixture was stirred overnight at room temperature. The pH was then adjusted to 2-3 with dil HCl, the acetone was removed in vacuo, and the aqueous phase was extracted three times with EtOAc.
The organic extracts were dried over anhydrous sodium sulfate and evaporated to dryness in vacuo, to give a colorless oil, which was used without purification (TLC, silica nhexane:EtOAc (1:1) showed a single component, R f 0.75).
Third, the Alloc-D-Tyr-OMe (5.31 g, 19 mmol) was dissolved in dry DMF (30 ml) and potassium carbonate (5.32 g, 38 mmol), allyl bromide (2.5 ml, 24 mmol), and n-Bu 4 NBr (1.9 g, 5 mmol) were added. The mixture was stirred for 24 h at room temperature. Then 1N sodium bisulfate was added and the mixture was extracted three times with EtOAc. The organic extracts were washed with brine, dried over anhydrous sodium sulfate and evaporated to dryness in vacuo. The resulting oil (5.8 g, 96%) was used without purification (TLC, silica n-hexane:EtOAc (2:1) showed a single component, R f 0. Fifth, the Alloc-D-Tyr(allyl)-OH (5.2 g, 17 mmol) and C 6 F 5 -OH (3.35 g, 18 mmol) in dry dioxane (20 ml) at 0 o C was treated with dicyclohexylcarbodiimide (3.7 g, 18 mmol).
After stirring 1 h at 0 o C, and another 1 h at room temperature, the mixture was filtered, and the filtrate was concentrated in vacuo. The resulting oil was crystallized from n-hexane and diethyl ether to give the product 5 as a white solid (6.2 g, 76% Step-5. Synthesis of amino acid 6. To N-Methyl-D-leucine (184 mg, 1.27 mmol) in dioxane:water (1:1, 10ml) was added sodium bicarbonate (1.07 g, 12.7 mmol) and Allocchloride (1.35 ml, 12.7 mmol) and the mixture was stirred overnight at room temperature.
The volatiles were then removed in vacuo, and the aqueous phase (pH 8) was extracted with diethyl ether. The aqueous phase was then adjusted to pH 2-3 with dil. HCl and was again extracted with ether. The ether extract was dried over anhydrous sodium sulfate and evaporated to dryness in vacuo to give Alloc-N-methyl-D-Leu-OH (270 mg, 93%). This material was dissolved in dry dioxane (5 ml) and pentafluorophenol (217 mg, 1.18 mmol) was added followed by dicyclohexylcarbodiimide (243 mg, 1.18 mol) and the mixture was stirred at 0 o C for 1 h then at room temperature for 2 h. The urea was removed by filtration and the filtrate was evaporated to dryness in vacuo, to afford the product as an oil, which was used without further purification. Step-6. Peptide assembly
Step-6A. Loading residue-6 on the resin. The amino acid 2 (320 mg, 1 mmol) was dissolved in a mixture of dry CH 2 Cl 2 and dry DMF (19:1, 15 ml) and dry N-methylmorpholine (510 µl, 4.7 mmol) was added. This mixture was added to freshly activated and dried CT-resin (1.2 g, 1.56 mmol/g, Novabiochem) and stirred at room temperature overnight. Methanol (5 ml) was then added and the mixture was agitated for 10 min. The resin was then filtered and washed successively with DMF (4 x 25 ml), MeOH (4 x 25 ml) and CH 2 Cl 2 (4 x 25 ml). The presence of amino acid on the resin was checked by treating a few resin beads with trifluoroacetic acid (TFA, 0.6%, v/v) in CH 2 Cl 2 (100 µl), and analysis by HPLC-MS.
Step-6B. Deprotection. To this resin (600 mg) under Ar-atmosphere in the dark was added a solution of Pd(PPh 3 ) 4 (200 mg, 0.7 mmol) and PhSiH 3 (1.3 ml, 10.6 mmol) in CH 2 Cl 2 (15 ml), and the mixture was agitated for 3 h. The resin was then filtered and washed successively with DMF (4 x 25 ml), CH 2 Cl 2 (4 x 25 ml) and DMF (4 x 25 ml). A few resin beads were treated with trifluoroacetic acid (TFA, 0.6%, v/v) in CH 2 Cl 2 (100 µl), and analysis by HPLC-MS was performed to ensure that deprotection was complete.
Step-6C. Coupling residue-5. To the resin was added 3 (251 mg, 1 mmol), diisopropylcarbodiimide (DIC) (126 mg, 1 mmol) and 1-hydroxybenzotriazole (HOBt) (306 mg, 2 mmol) in dry DMF (10 ml) and the mixture was agitated overnight at room temperature. The resin was then filtered and washed with DMF (4 x 25 ml) and CH 2 Cl 2 (4 x 25 ml). A few resin beads were treated with trifluoroacetic acid (TFA, 0.6%, v/v) in CH 2 Cl 2 (100 µl), and analysis by HPLC-MS was performed to ensure that coupling was >95%
complete. The Alloc group was then removed using the procedure in step-6B.
Step-6D. Coupling residue-4. This step was carried out as described for step-6C.
Step-6E. Coupling residue-3. For this step, the freshly prepared amino acid derivative 4 was used (see above). The compound 4 (382 mg, 1 mmol) and HOBt (306 mg, 2 mmol) in dry DMF (10 ml) was added to the resin, and the mixture was agitated overnight at room temperature. The resin was then filtered and washed with DMF (4 x 25 ml) and CH 2 Cl 2 (4 x 25 ml). A few resin beads were treated with trifluoroacetic acid (TFA, 0.6%, v/v) in CH 2 Cl 2 (100 µl), and analysis by HPLC-MS was performed to check that coupling was >95% complete. At this stage it is necessary to use nBu 3 SnH instead of PhSiH 3 as hydride donor in the deprotection step. Thus, under Ar-atmosphere in the dark a solution of Pd(PPh 3 ) 4 (140 mg, 0.49 mmol) and nBu 3 SnH (2 ml, 7.43 mmol) in CH 2 Cl 2 (15 ml) was added to the resin and the mixture was agitated for 3 h at room temperature. The resin was then filtered and washed successively with DMF (4 x 25 ml), CH 2 Cl 2 (4 x 25 ml) and DMF (4 x 25 ml). A few resin beads were treated with trifluoroacetic acid (TFA, 0.6%, v/v) in CH 2 Cl 2 (100 µl), and analysis by HPLC-MS was performed to ensure that deprotection was complete.
Step-6F. Coupling residue-2. For this step, the freshly prepared amino acid derivative 5 was used (see above). To the resin was added compound 5 (473 mg, 1 mmol) and HOBt (153 mg, 1 mmol) in dry DMF (10 ml), and the mixture was agitated overnight at room temperature.
The resin was then filtered and washed with DMF (4 x 25 ml) and CH 2 Cl 2 (4 x 25 ml). A few resin beads were treated with trifluoroacetic acid (TFA, 0.6%, v/v) in CH 2 Cl 2 (100 µl), and analysis by HPLC-MS was performed to check that coupling was >95% complete. Removal of the N-Alloc and O-allyl groups was performed using the procedure described in step-6E, with nBu 3 SnH as hydride donor. Then, a few resin beads were treated with trifluoroacetic acid (TFA, 0.6%, v/v) in CH 2 Cl 2 (100 µl), and analysis by HPLC-MS was performed to ensure that deprotection was complete.
Step-6G. Coupling residue-1. For this step, the freshly prepared amino acid derivative 6 was used (see above). To the resin was added compound 6 (435 mg, 1.1 mmol) and HOBt (168 mg, 1.1 mmol) in dry DMF (10 ml), and the mixture was agitated overnight at room temperature. The resin was then filtered and washed with DMF (4 x 25 ml) and CH 2 Cl 2 (4 x (100 µl), and analysis by HPLC-MS was performed to ensure that coupling was >95%
complete. Removal of the N-Alloc was performed using the procedure described in step-6E, with nBu 3 SnH as hydride donor.
Step-6H. Cleavage from the resin and purification. A solution of TFA in CH 2 Cl 2 (0.6% v/v, 20 ml) was added to the resin with agitation for 5 min at room temperature. The resin was then filtered, and the cleavage procedure was repeated four more times. The resin was then washed with methanol, and finally all organic filtrates were combined and evaporated to dryness in vacuo. The hexapeptide 1-OH (26 mg, >95% purity) was then obtained by preparative reverse-phase HPLC using a preparative C18 column and a gradient of 5-35% 
Peptide thioesters
The synthesis of the hexapeptide S-phenyl thioester 1-SPh, hexapeptide-SCoA thioester 1-SCoA, as well as the hexapeptide-PCP conjugate 1-S-PCP was achieved using methods described previously Woithe et al., 2007; Zerbe et al., 2004) .
Synthesis of hexapeptide S-phenyl thioester (1-SPh)
The hexapeptide 1-OH (2 mg) in freshly distilled DMF (1 ml) was stirred with PyBOP (1.2 eq), DIEA (1.2 eq) and thiophenol (2.4 eq) under nitrogen atmosphere. The reaction was monitored by LC/MS and was complete after 10 min. After lyophilisation, the resulting hexapeptide S-phenyl thioester (1-SPh) was purified by semi-preparative reverse-phase HPLC (C 18 Vydac 218TP1010, 250/10, pore diameter 300Å, particle size 5 µm) with a gradient of 5-100% MeCN+0.1% TFA in water+0.1% TFA in 5 column volumes at a flow rate of 5 ml/min. The corresponding peptide S-phenyl thioester was obtained in ≈90% yield.
ES-MS m/z = 992.4 ([M+H] + )
. Chemical shift assignments were obtained from 1D and 2D
1 H-NMR spectra and are given in Table- II.
Table-II.

Synthesis of hexapeptide-SCoA thioester (1-SCoA)
The peptide S-phenyl thioester 1-SPh (2 mg) and coenzyme A (4 eq) were stirred in sodium phosphate buffer (4 ml, 50 mM, pH 8.5). The reaction was complete after 120 min, as monitored by LC/MS and the product was purified by semi-preparative HPLC on a reverse phase C 18 column (Vydac 218TP1010, 250/10, pore diameter 300Å, particle size 5 µm) using Chemical shift assignments were obtained from 1D and 2D 1 H-NMR spectra and are given in Table- III.
Table-III.
Synthesis of hexapeptide-PCP conjugate (1-S-PCP)
The reaction mixture containing the following components at the concentrations given [apo-PCP (120 µM), hexapeptidyl-CoA thioester 1-SCoA (100 µM), B. subtilis Sfp (5 µM) and MgCl 2 (50 mM) in Tris/HCl buffer (50 mM, pH 7.5)], weres incubated at 37°C for 30 min.
The reaction was monitored by analytical HPLC (Vydac C18 218TP54 column, 250x4.6mm, pore diameter 300Å, particle size 5 µm) using a gradient of 5-100% MeCN+0.1% TFA in water+0.1% TFA over 4 column volumes at 1 ml/min. The conversion proceeded quantitatively. The resulting peptide-PCP conjugate 1-S-PCP was isolated by HPLC chromatography and the identity of the peptide-PCP conjugate was confirmed by MALDI-
, calc. mass: 11579).
Upon complete reaction, the mixture was dialysed against HEPES buffer (25 mM, pH 7.0, 50 mM NaCl), and the resulting solution containing the peptide-PCP conjugate 1-S-PCP was used in assays without further purification.
In Vitro Assays with OxyB
Assays with OxyB were carried out essentially as described earlier (Woithe et al., 2007; Zerbe et al., 2004) . The assay contained the following components at the concentrations given: peptide-PCP-conjugate 1-S-PCP (80 µM), OxyB (8 µM), recombinant spinach ferredoxin (20 µM), E. coli flavodoxin reductase (10 µM), NADPH (1 mM), glucose-6-phosphate (1 mM), glucose-6-phosphate-dehydrogenase (0.5 U) in HEPES buffer (25 mM, pH 7.0, 50 mM NaCl). Incubation at 30°C for 60 min was followed by addition of 1/10 volume of a 25 % v/v aqueous hydrazine solution. Further incubation at 30°C for 30 minutes yielded the peptide hydrazides, which were separated from proteins by solid phase extraction.
The peptidic fraction was analyzed by analytical HPLC (see Figure-6 ) on a reverse-phase C18 Zorbax Eclipse XDB column eluting with a gradient of 5-40% acetonitrile+0.1% TFA in water+0.1% TFA in 8 column volumes with a flow rate of 1 ml/min.
The major product isolated from the assay (Figure-6 Table- IV. The occurrence of epimeric products during peptide S-PCP-thioester formation and/or the OxyB assay and work-up has been documented in earlier studies Woithe et al., 2008) . 
Production and purification of enzymes
Production and purification of OxyB
Recombinant His 6 -tagged OxyB was produced and purified as described earlier (Zerbe et al., 2002) . Thus, recombinant His 6 -tagged OxyB was produced in E. coli BL21(DE3)pLysS, transformed with a plasmid (pOCI1047) containing the oxyB gene. TB medium (400 ml) with ampicillin (100 µg/ml) and chloramphenicol (34 µg/ml) was inoculated with a preculture and incubated at 24°C with shaking at 200 rpm. δ-Aminolevulinic acid (8 mg) was added at A 600 = 0.5. Cultures were induced with IPTG at A 600 = 1 and shaken at 22°C. At 20 h postinduction a second portion of δ-aminolevulinic acid (8 mg) was added and the cultures were harvested by centrifugation after another 24 h.
The cells were disrupted in phosphate buffer (50 mM potassium phosphate, pH 7.4, 10%
glycerol, 1 mM DTT, 1 mM PMSF, 1 mM benzamidine, 0.1% β-mercaptoethanol) by sonication. The E. coli cell-free extract containing His 6 -OxyB was applied to a Ni-NTA column (0.5 cm x 5 cm, Ni 2+ NTA superflow, Qiagen) pre-equilibrated with buffer A (potassium phosphate, pH 7.4, 50 mM, with KCl (300 mM), and imidazole (20 mM)), at a flow rate of 2 ml/min. After washing (20 column volumes of buffer A) the His 6 -tagged protein was eluted in buffer A with 300 mM imidazole, and dialysed against buffer B (TrisHCl (50 mM), pH 7.5, and EDTA (0.5 mM)). The protein was then chromatographed on MonoQ (HR10/10, GE Healthcare) in buffer B at a flow rate of 2 ml/min, and eluted with a linear gradient of 0 -0.4 M KCl over 100 ml with a flow rate of 1.5 ml/min. His 6 -OxyB eluted with 0.17 M KCl, and showed a single band by SDS-PAGE, gave an electrospray mass spectrum consistent with the expected mass, and the correct N-terminal sequence by Edman degradation. The concentration of the purified P450 was determined spectrophotometrically from CO difference UV spectra using dithionite-reduced heme and an extinction coefficient of 91 mM -1 cm -1 (Omura and Sato, 1964) .
The amino acid sequence of the His 6 -tagged OxyB (His-tag underlined) is shown below. 
Production and purification of spinach ferredoxin
Recombinant His 6 -tagged spinach ferredoxin was produced and purified as described earlier (Woithe et al., 2007) . Thus, a plasmid containing the His 6 -tagged ferredoxin gene (pOCI829) was introduced into E. coli BL21(DE3)pLysS (Novagen). The spinach ferredoxin was produced in LB medium containing ampicillin (100 µg/ml), chloramphenicol (34 µg/ml) and FeSO 4 (10 µM) at 37°C. The cultures were induced at A 600 = 1.4 with IPTG (0.1 mM)
and further cultivated at 30°C for 4 hours. Cell pellets were resuspended in phosphate buffer (20 ml, 50 mM, pH 7.4, 300 mM KCl, 1 mM DTT, 1 mM PMSF, 1 mM benzamidine, 0.1% 2-mercaptoethanol, 10% glycerol) and disrupted by sonication. After centrifugation (40'000 × g for 45 min), the supernatant was loaded onto a 7 ml Ni-NTA superflow column (Qiagen) and equlibrated with 20 ml buffer A (50 mM phosphate buffer pH 7.4, 300 mM KCl, 20 mM imidazole). After washing with 40 ml buffer A, recombinant spinach ferredoxin was eluted with 10 ml buffer A containing 300 mM imidazole. Fractions containing the red spinach ferredoxin were dialysed against 50 mM Tris-HCl buffer pH 7.5, 10% glycerol, flash-frozen and stored at -80°C. (Armengaud et al., 2000; Crispin et al., 2001; Tagawa and Arnon, 1962) . The solution concentration was determined by UV using ε 422 nm = 9700 cm -1 M -1 (Crispin et al., 2001 ).
The amino acid sequence of the His 6 -spinach ferredoxin is shown below, with the His-tag underlined:
Production and purification of PCP domain
A recombinant His 6 -tagged PCP domain from module-7 of the vancomycin NRPS (vpsC) from A. orientalis (residues 967-1043, including a Cys979Ser mutation, to avoid dimer formation through oxidation) was produced and purified as described earlier (Woithe et al., 2007) . Plasmid pOCI865 was introduced into E. coli Rosetta2(DE3)pLysS (Novagen). An overnight pre-culture (20 ml) was used to inoculate TB medium (400 ml) containing ampicillin (100 µg/ml) and chloramphenicol (34 µg/ml), with incubation at 37°C and shaking at 200 rpm. The cultures were induced at A 600 = 1.2 with IPTG (0.1 mM) and further cultivated at 22°C for 6 hours. Cell pellets were resuspended in 20 ml phosphate buffer (50 mM, pH 7.4, 1 mM DTT, 1 mM PMSF, 1 mM benzamidine, 0.1% 2-mercaptoethanol, 10% glycerol) and disrupted by sonication (three bursts of 60 s). After centrifugation (40'000 × g for 45 min), the supernatant was loaded onto a 7 ml Ni-NTA superflow column (Qiagen) and equilibrated with 20 ml buffer A (50 mM phosphate buffer pH 7.4, 300 mM KCl, 20 mM imidazole). After washing with 40 ml buffer A, recombinant PCP was eluted with 10 ml buffer A containing 300 mM imidazole. Eluted protein fractions were purified further The sequence of the PCP, which includes residues 967-1043 of VpsC and a His 6 -tag (underlined) and a Cys-to-Ser mutation (underlined), is shown below.
GSSHHHHHHS SGLVPRGSHM EKAPENETEK VLSALFAEIL SVDQVGVDDA
FQDLGGSSAL AMRLVARIRE ELGEDLPIRQ LFSSPTPAGL ARALAAK
Production and purification of E. coli NADPH-flavodoxin reductase
The production and purification of His 6 -tagged E. coli NADPH-flavodoxin reductase (ecoFlvR) was performed as described previously (Woithe et al., 2007) . The plasmid pOCI819
containing the required gene was introduced into E. coli BL21(DE3)pLysS cells (Novagen).
His 6 -tagged eco-FlvR was produced in LB medium containing ampicillin (100 µg/ml) and chloramphenicol (34 µg/ml) at 37°C. The cultures were induced at A 600 = 0.6 with IPTG (0.1 mM) and further cultivated at 37°C for 4 hours.
The cell pellet was resuspended in 20 ml phosphate buffer (50 mM, pH 7.4, 1 mM DTT, 1 mM PMSF, 1 mM benzamidine, 0.1% 2-mercaptoethanol, 10% glycerol) and disrupted by sonication (three bursts of 60 s). After centrifugation (40'000 × g for 45 min) the supernatant was loaded onto a 7 ml Ni-NTA superflow column (Qiagen) and equilibrated with 20 ml buffer A (50 mM phosphate buffer pH 7.4, 300 mM KCl, 20 mM imidazole). After washing with 40 ml buffer A, the recombinant eco-FlvR was eluted from the column with 10 ml buffer A containing 300 mM imidazole. Fractions containing bright yellow eco-FlvR were dialysed against 50 mM Tris-HCl buffer pH 7.5, 10% glycerol, flash-frozen and stored at -80°C.
The UV-Vis absorbance spectrum of the protein showed the typical maxima at 400, 456 nm and 483 nm (Jenkins and Waterman, 1994) . The flavodoxin reductase concentration was determined using the absorbance of bound FAD at 456 nm (ε = 7100 M -1 cm -1 ) (Fujii and Huennekens, 1974) . The purified protein showed a single band by SDS-PAGE and gave an Table-II. 1 H-NMR Chemical shift assignments for peptide 1-SPh (500 MHz at 300 K in DMSO-d 6 ). 
Residue NH C(α)-H C(β)-H Others
